Actinium Pharmaceuticals Inc., of New York, said an analysis of two trials with Actimab-A that enrolled 38 patients, 36 of whom were evaluable, validated its peripheral blast (PB) burden hypothesis, which suggests that patients below 200 blasts/µL have an increased response rate to Actimab-A while those above the threshold are unlikely to respond.